Nautilus Biotechnology (NASDAQ:NAUT) Issues Earnings Results

Nautilus Biotechnology (NASDAQ:NAUT) announced its quarterly earnings results on Tuesday. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02, FiscalAI reports.

Here are the key takeaways from Nautilus Biotechnology’s conference call:

• Nautilus is building its commercial organization (hired a VP of Global Sales plus two sales reps) and reiterates its go-to-market timeline with pre-orders in late 2026, customer installations beginning early 2027, and broad-scale availability expected in H1 2027.
• Early Access momentum is growing—Baylor College of Medicine is the first named EAP customer, collaborations with Buck and Allen Institutes are generating novel tau proteoform biology (including APOE-linked tau findings), and the company has verified/validated its service lab and standardized publication-quality results packages.
• Technical progress reduced execution risk: assay configuration iterations improved performance (flow cells, surface chemistry, models), the number of probes qualified as assay-compatible nearly tripled, and the team completed its largest high-cycle decode experiments while increasing sample complexity.
• Financially, Q1 operating expenses fell and the company ended the quarter with $143.4M in cash and a stated runway through 2027 (Q1 burn $12.8M), but near-term revenue is minimal and recognition from the Michael J. Fox Foundation grant has been delayed, with only about $0.5M expected for the year shifted into later quarters.

Nautilus Biotechnology Price Performance

Shares of Nautilus Biotechnology stock opened at $2.70 on Tuesday. The firm has a market cap of $341.46 million, a price-to-earnings ratio of -5.73 and a beta of 1.08. The stock’s 50-day moving average is $2.91 and its 200-day moving average is $2.23. Nautilus Biotechnology has a one year low of $0.62 and a one year high of $4.31.

Analysts Set New Price Targets

Several brokerages recently issued reports on NAUT. Guggenheim boosted their price objective on Nautilus Biotechnology from $2.50 to $4.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $4.00.

Insider Activity

In other news, CEO Sujal M. Patel bought 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were acquired at an average price of $2.61 per share, with a total value of $65,250.00. Following the transaction, the chief executive officer owned 10,366,721 shares in the company, valued at $27,057,141.81. This represents a 0.24% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 41.10% of the company’s stock.

Hedge Funds Weigh In On Nautilus Biotechnology

Hedge funds have recently made changes to their positions in the business. Hudson Bay Capital Management LP acquired a new stake in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $37,000. Virtu Financial LLC boosted its holdings in Nautilus Biotechnology by 19.6% during the fourth quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after purchasing an additional 3,849 shares during the last quarter. Captrust Financial Advisors bought a new position in Nautilus Biotechnology in the fourth quarter valued at $66,000. Bank of America Corp DE increased its stake in Nautilus Biotechnology by 37.1% in the 4th quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock valued at $83,000 after buying an additional 13,363 shares during the last quarter. Finally, Acadian Asset Management LLC increased its stake in Nautilus Biotechnology by 468.3% in the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock valued at $51,000 after buying an additional 50,871 shares during the last quarter. 50.71% of the stock is owned by institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.